… Research (MJFF) has awarded approximately $1 million to fund five projects that will investigate dyskinesias, the … side-effect of treatment and are distinct from the tremors commonly associated with Parkinson’s disease. The program … will study the production of these brain chemicals and how they potentially affect changes in parkinsonism and …

… non-coding RNA (RNA that does not encode a protein) that shows a five-fold decrease within the brains of people with Parkinson’s disease (PD) compared to similarly aged healthy individuals. This RNA is also … Access to Data and Biospecimens … Antony A. Cooper, PhD …

… upon the research from a prior grant: First-in-human Trial to Assess the Safety and Tolerability of PD01, the First … Vaccine Study Rationale: PD01A is an alpha-synuclein-targeting vaccine. Accumulation and/or aggregation of … clinical development of PD01A. Trial phase:  IB Final Outcome AFFITOPE® PD01A was safe and well tolerated, achieving …

… Study Rationale:                    The dysfunction of the systems responsible for the clearance … disease (PD). The lysosome is an important sub-cellular compartment for alpha-synuclein disposal. Among the many … for this degradation, major attention has been given to glucocerebrosidase (GCase). Several reports have …

… in the Pathogenesis of Parkinson's Disease Promising Outcomes of Original Grant: In our original project we used … mutations. Additionally, we found that treatment with drugs to inhibit LRRK2 increased GCase activity not only in … This is important as therapeutic development of drugs targeting either the inhibition of LRRK2 or activation of GCase …

… Promising Outcomes of Original Grant: The goals of the original grant were to develop PET (a non invasive imaging technique used in the … since impaired dopaminergic neurotransmission has been shown to be a key feature of LRRK2 mutations-related … A. Jon Stoessl, CM/MD/FRCPC/FCAHS …